Alto Neuroscience (ANRO) Cash from Operations (2023 - 2026)

Alto Neuroscience has disclosed Cash from Operations across 4 years of filings, most recently posting 27091000.0 for Q1 2026.

• Cash from Operations for Q1 2026 came in at 27091000.0, down 63.63% year-over-year; the trailing twelve-month figure through Mar 2026 was 62304000.0 (down 17.56% YoY), and the FY2025 annual result was 51769000.0, down 9.16% from the prior year.
• Cash from Operations came in at 27091000.0 for Q1 2026 at Alto Neuroscience, down from 11516000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 6635000.0 in Q2 2023 to a low of 27091000.0 in Q1 2026.
• The 4-year median for Cash from Operations is 11524000.0 (2023), against an average of 12287076.92.
• Across the five-year window, Cash from Operations plunged 76.25% in 2024 and gained 15.42% in 2025, its largest moves.
• Alto Neuroscience's Cash from Operations stood at 11524000.0 in 2023, then declined by 12.99% to 13021000.0 in 2024, then advanced by 11.56% to 11516000.0 in 2025, then plunged by 135.25% to 27091000.0 in 2026.
• The last three Cash from Operations figures came in at 27091000.0 (Q1 2026), 11516000.0 (Q4 2025), and 9918000.0 (Q3 2025), per Business Quant data.